Saccharomyces boulardii as effective probiotic against Salmonella typhimurium in Mice

Shahlaa M. Salih* Manhal F. Ahmed* Abeer Y. Abdul-Kareem**

*Al-Nahrain University - College of Science
** University of Anbar - College of Medicine

ARTICLE INFO
Received: 6 / 5 /2012
Accepted: 9 /6 /2013
Available online: 03/11/2014
DOI: 10.37652/juaps.2013.104796

ABSTRACT

This study was designed to investigate the protective role of Saccharomyces boulardii on intestinal section of mice infected with Salmonella typhimurium. Mice were divided into four groups. A control group is uninfected with bacteria represent (negative control) , a second group was infected with bacteria S.typhimurium 0.1 ml (2.5 ×10^7 cfu/ ml) only represent (positive control) , the third group Induced mice received oral dose of S. boulardii 0.1ml (1×10^9 cfu/mL). Treated mice received S. boulardii (1×10^9 cfu/mL) orally for 7 days, followed by Salmonella infection. At the end of the experimental period the histological Results showed that administration of S. typhimurium alone resulted in a necrosis, degenerative changes and inflammatory cells infiltration in intestinal sections as compared with normal section taken from uninfected mice, while pretreatment with the S. boulardii ameliorate this effect.

Keywords: Saccharomyces boulardii, probiotic, Salmonella typhimurium, Mice.

Introduction:

In human, Salmonella spp. Are responsible for over one billion infections annually, with consequences ranging from self-limiting gastroenteritis to typhoid fever [1]. To initiate disease, Salmonella first adheres to and then induces its own uptake into intestinal epithelial cells through a specialized mechanism involving injection of virulence factors into host cells by a type III protein secretion system (TTSS) [2].

Gram-negative Salmonella sp. Is a common bacterial enteropathogen and is widely used in laboratory studies aimed toward understanding the basis of mucosal immune responses and diseases such as gastroenteritis and typhoid. Most laboratory studies are carried out using S.Typhimurium in mice, where adissemintated infection with some similarities to human typhoid is observed. Typhoid fever affects more than 20 million individuals and causes more than 220,000 deaths annually [3,4].

In recent years, worldwide interest for the use of functional foods containing probiotic microorganisms for health promotion and disease prevention has increased significantly and according to the Food and Agriculture Organization and the World Health Organization, a probiotic is “a live microorganism which, when administered in adequate amounts, confers a health benefit to the host”. [5] Lyophilized Saccharomyces boulardii is probiotic yeast used worldwide for the prevention and treatment of a variety of diarrheal diseases [6]. In the case of infectious diarrhea, administration of S. boulardii to animals provides protection against intestinal lesions caused by several diarrheal pathogens [7].

Indeed, controlled clinical trials have shown that oral administration of S boulardii could treat or prevent gastrointestinal diseases such as antibiotic-associated diarrhea [8], recurrent Clostridium difficile-associated diseases [9], traveller diarrhea [10], children acute diarrhea [11], bowel disease such as Crohn's disease and ulcerative colitis [12,13] and irritable bowel syndrome [14]. This study was carried out to evaluate the treatment role of Saccharomyces boulardii on mice infected with Salmonella typhimurium.
Materials and Methods:

Microbial isolates:
S. typhimurium was supplied by Central Public Health Lab. Which was previously isolated from stool sample of infant suffer from diarrhea, S. boulardii was bought as commercial lyophilized yeast (Ultra-Levure®, BIOCODEX, France).

Bacterial culture:
S. typhimurium strain was grown overnight at 37°C in brain heart infusion broth. This activated culture was centrifuged at 3,000 rpm for 5 min, washed with sterile phosphate-buffered saline (PBS, pH 7.4), and resuspended in PBS to a final concentration of 2.5 × 10⁷ bacteria/ml [15].

Determination of the S. typhimurium susceptibility to antibiotics.
Disk diffusion test was used for testing susceptibilities of isolates to different antibiotics. Ten ml of nutrient broth medium were inoculated with bacterial isolates, the cultures were incubated at 37°C to mid log phase (18hrs). 100µl of inoculated broth then transferred to Muller-Hinton agar plates. A sterile cotton swab was used in three different planes to obtain an even distribution for inoculating triplicate plates [16].

With sterile forceps, the selected antibiotic disks were placed on the inoculated plate. All plates were incubated at 37°C for 24 hrs in an inverted position. Then diameter of inhibition zone was noted and measure by a ruler in mm.

Experimental design:
Twenty adults albino male mice were randomly divided into four groups designated as 1, 2, 3, and 4. Each group consists of 5 mice, and subjected to the following treatments according to [17].

Group 1: This group was used as a negative control.
Group 2: This group was dosed with 0.1ml. of 2.5 × 10⁷cfu/ml S. typhimurium culture and considered as positive control.
Group 3: This group was dosed with 0.1ml of 1 × 10⁹cfu/ml S. boulardii culture.
Group 4: This group was dosed with 0.1ml of 1 × 10⁹cfu/ml S. boulardii culture, and infected with 0.1ml of 2.5 × 10⁷ cfu/ml culture of S. typhimurium.

Mice were dosed with a single dose( 0.1 ml) of 1 × 10⁹cfu/ml S. boulardii culture daily by oral administration for 7 consecutive days. After 7 days treatment, at the 8th day of experiment period, each mouse was given 0.1 ml of 2.5×10⁷ Salmonella culture by oral administration. After 6th day of infection with S. typhimurium, mice were sacrificed by cervical dislocation and collected to evaluate histological effect. Pieces were taken from intestine and put in petridishes containing physiological salty solution to remove the fatty tissues and sticky bundles, then the organ was kept in test tubes containing 10% formalin solution then wash, dehydrated, embedded in paraffin, sectioned at 4-5 micron thickness preparation [18]. The staining method was performed by using hematoxilin and eosin as a routine work for histological studies[19].

Results and Discussion:
Susceptibility to different antibiotics as shown in table 1 revealed that S. typhimurium was sensitive to Carbencillin, Ciprofloxacin and Rifampicin and resistant to other antibiotics.

Results indicated that mice intestinal sections taken from the control group showed normal structure appearance of villi without any pathological changes as shown in figure 1A. While, in intestinal sections taken from mice infected with S. typhimurium showed shedding and necrosis of intestinal mucosa and villi inside the lumen of the intestine figure 1 B. Mice fed with S. boulardii showed normal villi appearance, while mice infected with S. typhimurium and pretreated with S. boulardii revealed shortening of the intestinal villi with thinning of the intestinal mucosa and ameliorate cytotoxic effect of Salmonella as shown in figure 1 C and D. Susceptibility of S. typhimurium to different antibiotics exhibited their resistance to different antibiotics used in this study. These results were close to those of CDC [20] who found that S. typhimurium isolates resisted chloramphenicol, ampicillin, streptomycin, and tetracycline the drug resistance genes can be transferred among many species of enteric bacteria.

Results showed that intestinal section of mice infected with Salmonella resulted in widening and oedema in the villi with slight exist of inflammatory cells. This might be attributed to its ability to destroy M cells found within pyer's patches. It's known that S. typhimurium grows primarily inside the macrophages
of liver and spleen. It has been shown that within 30 min of infection, invasive S. typhimurium entered M cells found within the follicle-associated epithelium (FAE) of Peyer's patches. At 60 min, internalized bacteria were cytotoxic for the M cells and the dead cell formed a gap in the FAE, which allowed bacteria to invade adjacent enterocytes or rapidly migrate to a number of sites in the body, including the spleen and liver, where they replicated inside phagocytic cells[21].

Results indicated that pretreatment with S.boulardii reduce the effect of Salmonella in intestinal pattern of mice. This protective effect could be due to immunomodulation or competition for nutrients or adhesion sites. The antagonism effect of Saccharomyces against Salmonella and E.coil mentioned by Gedek [22] who reported that the mannose in the cell wall may cause the yeast to act as a decoy for the attachment of pathogens the yeast acts as a pathogen adherent microflora (PAM) and binds organisms such as Salmonella that may enter the gastrointestinal tract before the bacteria can attach to the chicken’s intestinal wall.

Rodrigues et al [23] reported that the immunomodulation effect of S. boulardii has been shown to increase intestinal secretory IgA production. sIgA is thought to inhibit the close association of pathogenic bacteria with the mucosal epithelium, and so to reduce bacterial penetration and more efficient clearance of S. bouladi against E.coli B41 in mice was correlated with earlier production of IFN-γ and IL-12 which are involved in the T-helper 1 response.

Another study proved that S. boulardii interferes with the host cell signalling pathways and decreases the expression of inflammation-associated cytokines such as interleukin 8 (IL-8), IL-6, IL-1β, tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) [24], [25] and [26].

Table 1: Susceptibility of Salmonella typhimurium to antibiotics.
Section in small intestine of mice treated with S. boulardii and infected with S. typhimurium showing the shortening of the intestinal villi with thinning of the intestinal mucosa (arrows) (HE) ×100.

References:
1- Galán JE, Bliska JB (1996) Cross-talk between bacterial pathogens and their host cells. Annu Rev Cell Dev Biol 12: 221–255.

Find this article online 2- Galán JE, Collmer A (1999) Type III secretion machines: bacterial devices for protein delivery into host cells. Science 284: 1322–1328.
3-Crump, J.A.,Luby, S.P.,and Mintz, E.D.(2004). The global of typhoid fever. Bull.Worled Health Organ.82.346-353.
4-Woc-Colbum,L.,and Bobak,D.A. (2009). The expanding spectrum of diseases due to salmonella: an international perspective. Curr.Infect.Dis.Rep.11,120-124
5- FAO/WHO (2002) Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada.
6- Czerucka D, Piche T, Rampal P (2007) Review article: yeast as probiotics-Saccharomyces boulardii. Aliment Pharmacol Ther 26: 767–778.
7- Find this article online 7- Czerucka D, Rampal P (2002) Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4: 733–739.
8- Kotowska, M., Albrecht, P., and Szajewska, H. (2005). Saccharomyces boulardii in the prevention of antibiotic- associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 21, 583-590.
9- McFarland, L. V. (2006). Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101, 812-822.
10- McFarland, L. V. (2007). Meta-analysis of probiotics for the prevention of traveler• fs diarrhea. Travel Med Infect Dis 5: 97-105. 
11- Htwe, K., Yee, K. S., Tin, M., and Vandenplas, Y. (2008). Effect of Saccharomyces boulardii in the Treatment of Acute Watery Diarrhea in Myanmar Children: A Randomized Controlled Study. Am J Trop Med Hyg 78, 214-216.
12- Guslandi, M., Giollo, P., and Testoni, P. A. (2003). A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15, 697-698
13- Guslandi, M., Mezzi, G., Sorghi, M., and Testoni, P. A. (2000). Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45, 1462-1464.
14- Maupas, J., Champemont, P., and Delforge, M. (1983). Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double-blind, placebo-controlled-study. Med Chir Dig 12, 77-79.
15- Lillian, N.M.; Elizabeth N.; and Jacques R. Nicoli, Protection by Lactobacillus acidophilus unv-h2b20 against experimental oral infection with Salmonella typhimurium in gnotobiotic and conventional mice. brazilian journal of microbiology (2001).
16- Atlas, R. M.; Brown, A. E. and Parks L. L. (1995). Laboratory Manual of Experimental Microbiology (1st Ed.). Mosby. Inc. Missouri.
17- Mahzounieh, M.; Karimi, T., and Marjianian, R., (2006). The preventive of Saccharomyces boulardii in pathogenesis of Salmonella typhimurium in experimentally infected rats. Pak. J. of Bio.Scien., 9(4): 632-635
18- Lin WH, Yu B, Lin CK, Hwang WZ, Tsen HY. (2007). Immune effect of heat-killed multistrain of Lactobacillus acidophilus against Salmonella typhimurium invasion to mice. Appl Microbiol.; 102 (1):22-31
19- Bankroft, L. (1980). Basic histological techniques; 4th ed; an Arboer science publishers. Pp: 130-145.
20- CDC.(2009) National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2006. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC,
21- Jones, B. D. & Falkow, S. (1996). Salmonellosis: host immune responses and bacterial virulence determinants. Annu Rev Immunol 14, 533–561.
22- Gedek, B. (1999) Adherence of E.coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of S.boulardii. Mycoses 42(4): 261-64
23- Rodrigues, A. C., Cara, D. C., Fretez, S. H. G. G., Cunha, F. Q., Vieira, E. C., Nicoli, J. R. & Vieira, L. Q. (2000). Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89, 404–414.
24- Dahan, S., Dalmasso, G., Imbert, V., Peyron, J. F., Rampal, P., and Czerucka, D. (2003).
Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71, 766-773

26- Mumy, K. L., Chen, X., Kelly, C. P., and McCormick, B. A. (2007). Saccharomyces boulardii interferes with Shigella pathogenesis by post-invasion signaling events. Am J Physiol Gastrointest Liver Physiol 294, G599-609.

**Salmonella typhimurium**

في الفئران المصابة ببكتريا Sacchromyces boulardii

شهلاء مهدي صالح
منهل فاروق احمد
عبير يوسف عبد الكريم

E.mail: dean_coll.science@uoanbar.edu.iq

**الخلاصة:**

أجريت هذه الدراسة لتقييم الدور الوقائي لخميرة Sacchromyces boulardii في اماع الفئران المصابة ببكتريا S.typhimurium , ومجموعة ثانية تم اصابتها ببكتريا S.typhimurium فقط تمثل (positive control) أما المجموعة الثالثة جرعت بخميرة Sacchromyces boulardii لمدة 7 ايام بعد ذلك تم إصابتها ببكتريا S.typhimurium (negative control) لمدة 7 ايام بعد ذلك تم إصابتها ببكتريا S.typhimurium سبب تباثات إصابة الفئران بالخراجات الالتهابية التي تسببها انحلال الخلايا والخلايا الالتهابية في الفئران المصابة. كما أظهرت النتائج أن معالجة الفئران بالخراجات المأخوذة من الفئران المصابة ببكتريا S.typhimurium البكتيريا السببية السببية في الفئران المصابة.